GBG Forschungs GmbH (German Breast Group)

A small hypoxia signature predicted pCR response to bevacizumab in the neoadjuvant GeparQuinto breast cancer trial (2020) Karn T, Meissner T, Weber KE, Solbach C, Denkert C, Engels K, Fasching P, et al. Journal article Germline (G)BRCA1/2 Mutations (M) and Hematological Toxicities in Patients (PTS) with Triple Negative Breast Cancer (TNBC) Treated with Neoadjuvant Chemotherapy (NACT) (2020) Furlanetto J, Moebus V, Schneeweiss A, Rhiem K, Tesch H, Blohmer JU, Luebbe K, et al. Conference contribution A Randomized, Double-Blind, Phase III Trial of Neoadjuvant Chemotherapy (NACT) with atezolizumab/Placebo in Patients with Triple-Negative Breast Cancer (TNBC) Followed by Adjuvant Continuation of atezolizumab/Placebo (Gepardouze) (2020) Loibl S, Jackisch C, Seiler S, Rastogi P, Huober L, Denkert C, Schneeweiss A, et al. Conference contribution Germline Mutation Status and Therapy Response in High-Risk Early-Stage Breast Cancer: a Secondary Analysis of the Geparocto Randomized Clinical Trial (NCT02125344) (2020) Pohl-Rescigno E, Hauke J, Rhiem K, Moebus V, Furlanetto J, Denkert C, Fasching P, et al. Conference contribution AGO Recommendations for the Diagnosis and Treatment of Patients with Locally Advanced and Metastatic Breast Cancer: Update 2020. (2020) Ditsch N, Untch M, Kolberg-Liedtke C, Jackisch C, Krug D, Friedrich M, Janni W, et al. Journal article, Review article Neoadjuvant paclitaxel/olaparib in comparison to paclitaxel/carboplatinum in patients with HER2-negative breast cancer and homologous recombination deficiency (GeparOLA study) (2020) Fasching P, Link T, Hauke J, Seither F, Jackisch C, Klare P, Schmatloch S, et al. Journal article MGMT promoter methylation in triple negative breast cancer of the GeparSixto trial (2020) Jank P, Gehlhaar C, Bianca L, Caterina F, Andreas S, Karn T, Marmé F, et al. Journal article Tumor mutational burden and immune infiltration as independent predictors of response to neoadjuvant immune checkpoint inhibition in early TNBC in GeparNuevo (2020) Karn T, Denkert C, Weber KE, Holtrich U, Hanusch C, Sinn BV, Higgs BW, et al. Journal article Trial watch : the gut microbiota as a tool to boost the clinical efficacy of anticancer immunotherapy (2020) Daillere R, Derosa L, Bonvalet M, Segata N, Routy B, Gariboldi M, Budinska E, et al. Journal article, Review article Association of Germline Variant Status with Therapy Response in High-risk Early-Stage Breast Cancer: A Secondary Analysis of the GeparOcto Randomized Clinical Trial (2020) Pohl-Rescigno E, Hauke J, Loibl S, Möbus V, Denkert C, Fasching P, Kayali M, et al. Journal article